Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

Stopped early · Not applicable

Conditions studied: Parkinson's Disease

In brief

Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements. To date, there are no objective measures of these movements. The purpose of this study is to measure the reduction of the movements by amantadine and/or topiramate using an objective measure.

Key facts

Study ID

NCT00794313

Run by

Oregon Health and Science University

People needed

3

Starts

2009-09-01

Expected to finish

2010-06-01

Last updated by the study team

2018-02-01

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Parkinson's Disease
• At least 21 years of age
• Must be taking Oral levodopa
• Must have dyskinesias by history or previous clinical observation

You may not qualify if…

• Significant cognitive impairment as measured by the Montreal Cognitive Assessment (MOCA) score of < 25
• Subjects with unstable medical or psychiatric conditions (including hallucinations)
• Use of dopamine receptor blocking medications (e.g., neuroleptics, certain antiemetics, tetrabenazine)
• History of unstable medical conditions (ie active cardiovascular disease, recent unwellness or surgery etc.)
• Use of anticoagulants
• Current substance abuse
• Previous adverse event on amantadine

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.